reported that only 33% of the CDK12-altered advanced PCa patients had a prostate-specific antigen (PSA) response and an increased progression-free survival of 5.4 months when treated with anti-PD-1 therapy [16]. Here, CDK12 is linked to posterior cortical atrophy.